Brain scans reveal how Weight-Loss drugs rewire appetite in teens vs adults
NCT ID NCT07021937
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study investigates how semaglutide (the drug in Ozempic and Wegovy) changes brain activity related to appetite and eating in people with obesity. Researchers will compare teenagers (ages 12–18) and adults (ages 30–45) using brain scans and meal tests to see if the drug affects the brain differently by age. The goal is to understand how these popular weight-loss medications work in the developing brain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If successful, this could reveal how GLP-1 drugs change brain activity in young people with obesity, potentially leading to more tailored treatments.
What could go wrong
This is a Phase 3 trial with 120 participants, so results may not apply to everyone. The study focuses on brain scans and appetite measures, not long-term weight outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact